Pharmacogenomics promises clearer efficacy signals, fewer safety events, and stronger labels—yet it rarely features in clinical trials. Despite strong evidence, adoption remains slow, fragmented, and operationally complex. This piece explores why PGx still struggles to become…
Read more →
DNA ME is inviting a select group of laboratories to join a special twelve-month partnership that brings an entire sequencing workflow into their facility. See how a small number of labs become founding partners while keeping their independence—and what it means for their daily…
Read more →
DNA ME invites pioneering researchers to join a six-month closed beta unlike any traditional trial. Designed for scientists who can’t wait weeks for results, Pioneer Access promises rapid sequencing, direct lab collaboration, and early influence on next-generation…
Read more →
Discover how DNA questions are quietly becoming everyday questions – in medicine, environment, food, agriculture and beyond. Our Newscenter shares real‑world stories, field insights and future‑shaping ideas. Subscribe to see where local DNA analysis is already changing…
Read more →
DNA ME is breaking the typical biotech launch mold with two closed beta programs—for individual researchers and labs. Discover why they’re testing their sequencing platform in real-world conditions before full release, and how collaborators shape the final product for diverse…
Read more →
I fell for Oxford Nanopore’s MK1B during my nano-biophysics master’s—and never got over it. From hacked workflows to remote AI “turbo control,” this story shows what happens when I - as nanobiophysics student - fell in love with a pocket-sized DNA sequencing device — and…
Read more →
Luck quietly shapes our genomes, our victories, and our extinctions—yet we still worship “hard work” as if effort alone decided who thrives. This piece follows a tiny genetic tweak, the fall of dinosaurs, and why reading DNA today means spotting small advantages before fate…
Read more →
